Procalcitonin- and Presepsin-Guided Antibiotics for Early-Onset Sepsis in Preterm Infants: A Randomized Clinical Trial
Importance: Early administration of antibiotics in the absence of proven sepsis, such as for treatment of early-onset sepsis (EOS), has been associated with adverse outcomes in very preterm infants. Reference values for procalcitonin (PCT) and presepsin (P-SEP) have been established in preterm infants. Objective: To determine whether PCT- and P-SEP-guided antibiotic treatment for EOS was noninferior to universal antibiotic treatment with respect to survival without major morbidity. Design, Setting, and Participants: This randomized multicenter noninferiority clinical trial was conducted in 17 Italian neonatal intensive care units between June 1, 2023, and January 31, 2025, among preterm infants born at 25 weeks and 0 days to 31 weeks and 6 days of gestation. Interventions: Enrolled infants were randomly allocated to receive either PCT- and P-SEP-guided antibiotic treatment, administered if PCT and P-SEP levels exceeded prespecified thresholds, or universal antibiotic treatment for EOS. Main Outcomes and Measures: The composite primary outcome was defined as survival without late-onset sepsis (LOS), bronchopulmonary dysplasia, grade 3 or 4 intraventricular hemorrhage (IVH), grade 2 or higher necrotizing enterocolitis (NEC), periventricular leukomalacia (PVL), or stage 3 or higher retinopathy of prematurity (ROP). The prespecified noninferiority margin was -5 percentage points. Both a primary intention-to-treat analysis and a secondary per-protocol analysis were performed, as recommended for noninferiority trials. Results: The study enrolled and randomized 283 very preterm infants (mean [SD] gestational age, 30.2 [2.2] weeks; 161 girls [57%]); 143 received procalcitonin- and presepsin-guided treatment and 140 received universal antibiotic treatment. The primary outcome did not differ between the PCT- and P-SEP-guided treatment group and the universal antibiotic treatment groups (76 of 143 [53%] vs 77 of 140 [55%]; risk difference, -1.8 percentage points; 90% CI, -11.9 to 8.3 percentage points; P = .32). Noninferiority of PCT- and P-SEP-guided treatment compared with universal treatment was not demonstrated, because the lower bound of the 2-sided 90% CI crossed the prespecified noninferiority margin. The risk differences for LOS, IVH, NEC, PVL, ROP, and death were not significantly different between the groups. PCT and P-SEP values were not different between the groups. No patient developed EOS. Conclusions and Relevance: In this randomized clinical trial conducted among neonates born between 25 weeks and 0 days and 31 weeks and 6 days of gestation, a PCT- and P-SEP-guided strategy for the treatment of EOS did not demonstrate noninferiority to universal antibiotic treatment with respect to survival without major morbidity. Within the limits of this study, these findings do not support the routine use of a biomarker-guided approach as an alternative to universal treatment for this high-risk population. Trial Registration: Clinicaltrials.gov identifier: NCT05796115.
Authors
- Gianluca Lista (ORCID: https://orcid.org/0000-0002-6636-5673)
- Stefano Martinelli (ORCID: https://orcid.org/0000-0002-2155-8535)
- Valentina Favero
- Marcello Napolitano (ORCID: https://orcid.org/0000-0003-0288-3858)
- Paola Lago (ORCID: https://orcid.org/0000-0002-4866-0775)
- Marzia Maino
- Pasqua Betta (ORCID: https://orcid.org/0000-0002-2635-4945)
- Diego Gazzolo (ORCID: https://orcid.org/0000-0002-0643-2555)
- Cristian Achille (ORCID: https://orcid.org/0000-0003-4528-7079)
- Carlo Dani (ORCID: https://orcid.org/0000-0002-1639-621X)
- Chiara Poggi (ORCID: https://orcid.org/0000-0003-2125-3827)
- Luigi Corvaglia (ORCID: https://orcid.org/0000-0002-8119-7743)
- Eloisa Gitto (ORCID: https://orcid.org/0000-0001-7442-8630)
- Stefano Ghirardello (ORCID: https://orcid.org/0000-0002-0621-155X)
- Chiara Cafforio
- Alice Proto (ORCID: https://orcid.org/0000-0002-1515-9079)
- Massimo Agostino Agosti (ORCID: https://orcid.org/0000-0003-1828-821X)
- Maria Grazia Capretti (ORCID: https://orcid.org/0000-0002-0124-0829)
- Elvira Bonanno
- Imma Rulli
- Carlo Pietrasanta (ORCID: https://orcid.org/0000-0002-1019-4422)
- Valentina Pivetti
- Monica Fumagalli (ORCID: https://orcid.org/0000-0002-0186-0710)
- Luca Boni (ORCID: https://orcid.org/0000-0003-2217-4047)
- G Maffei
- Sara De Sanctis
- Simona Perniciaro (ORCID: https://orcid.org/0000-0002-3849-0362)
- Camilla Cattaneo (ORCID: https://orcid.org/0000-0002-3671-4334)
- Ciro Barone
- Carmine Mattia (ORCID: https://orcid.org/0009-0008-0308-1543)
- Chryssoula Tzialla
- Maria Lucente
- Valeria Angela Fasolato
- Monica Zannoni
Institutions
- University of Messina (IT)
- University of Insubria (IT)
- University of Milan (IT)
- Ospedale Filippo Del Ponte Varese (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Chieti-Pescara (IT)
- Ospedali Riuniti di Foggia (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- AULSS 2 Marca Trevigiana (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Azienda Ospedaliera di Cosenza (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Policlinico Universitario di Catania (IT)
- Ospedale dei Bambini Vittore Buzzi (IT)
- Ca' Foncello Hospital (IT)
- Ospedale Policlinico San Martino (IT)
- Policlinico San Matteo Fondazione (IT)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
- Azienda Ospedaliera Carlo Poma (IT)
- University of Florence (IT)
- University of Bologna (IT)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.43418
- Primary Topic
- Neonatal and Maternal Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00